iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Raises FY2026 Sales Guidance from $91.000M-$96.000M to
iRadimed (NASDAQ: IRMD ) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate. Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs $91.300 million estimate.
Story updates
12:16:47 PM UTC
SquawkNews
iRadimed (NASDAQ: IRMD ) affirms FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$2.05 vs $1.91 analyst estimate..
iRadimed (NASDAQ: IRMD ) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate.
Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs $91.300 million estimate.